{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:24:25Z","timestamp":1770747865847,"version":"3.49.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s11864-017-0442-8","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T07:18:02Z","timestamp":1486624682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer"],"prefix":"10.1007","volume":"18","author":[{"given":"Matteo","family":"Lambertini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Viglietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam F.","family":"Pond\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"issue":"1","key":"442_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21320","volume":"66","author":"CE DeSantis","year":"2016","unstructured":"DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31\u201342.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"442_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","volume":"16","author":"HA Azim","year":"2014","unstructured":"Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"442_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000441371","volume":"10","author":"AH Partridge","year":"2015","unstructured":"Partridge AH. Chemotherapy in premenopausal breast cancer patients. Breast Care. 2015;10(5):307\u201310.","journal-title":"Breast Care"},{"issue":"27","key":"442_CR4","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","volume":"34","author":"AH Partridge","year":"2016","unstructured":"Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308\u201314.","journal-title":"J Clin Oncol"},{"issue":"1","key":"442_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/23809000.2016.1139458","volume":"1","author":"F Poggio","year":"2016","unstructured":"Poggio F, Levaggi A, Lambertini M. Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients. Expert Rev Quality Life Cancer Care. 2016;1(1):5\u20137.","journal-title":"Expert Rev Quality Life Cancer Care"},{"issue":"1","key":"442_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/bmt.13.67","volume":"3","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Azim Jr HA. Adjuvant hormonal therapy in young breast cancer patients. Breast Cancer Management. 2014;3(1):1\u20134.","journal-title":"Breast Cancer Management."},{"issue":"9793","key":"442_CR7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384.","journal-title":"Lancet"},{"issue":"21","key":"442_CR8","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"\u2022\u2022 Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255\u201369. ASCO guidelines on adjuvant endocrine therapy for breast cancer patients.","journal-title":"J Clin Oncol"},{"issue":"11","key":"442_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2013.52.8877","volume":"32","author":"KJ Ruddy","year":"2014","unstructured":"Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151\u20136.","journal-title":"J Clin Oncol"},{"issue":"19","key":"442_CR10","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","volume":"31","author":"AW Loren","year":"2013","unstructured":"\u2022\u2022 Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500\u201310. ASCO guidelines on fertility preservation in cancer patients.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"442_CR11","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","volume":"24","author":"FA Peccatori","year":"2013","unstructured":"\u2022\u2022 Peccatori FA, Azim Jr HA, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160\u201370. ESMO guidelines on fertility preservation in cancer patients.","journal-title":"Ann Oncol"},{"issue":"1","key":"442_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0545-7","volume":"14","author":"M Lambertini","year":"2016","unstructured":"\u2022 Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14(1):1. International recommendations on fertility preservation in cancer patients.","journal-title":"BMC Med"},{"key":"442_CR13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.breast.2015.12.010","volume":"26","author":"S Paluch-Shimon","year":"2016","unstructured":"\u2022 Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87\u201399. International recommendations on the management of breast cancer in young women.","journal-title":"Breast"},{"issue":"12","key":"442_CR14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1080\/14656566.2016.1199685","volume":"17","author":"M Lambertini","year":"2016","unstructured":"Lambertini M, Poggio F, Vaglica M, et al. News on the medical treatment of young women with early-stage HER2-negative breast cancer. Expert Opin Pharmacother. 2016;17(12):1643\u201355.","journal-title":"Expert Opin Pharmacother"},{"key":"442_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2015.11.002","volume":"42","author":"L Del Mastro","year":"2016","unstructured":"Del Mastro L, Rossi G, Lambertini M, et al. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. Cancer Treat Rev. 2016;42:18\u201323.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"442_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.breast.2014.05.024","volume":"23","author":"N Tomasi-Cont","year":"2014","unstructured":"Tomasi-Cont N, Lambertini M, Hulsbosch S, et al. Strategies for fertility preservation in young early breast cancer patients. Breast. 2014;23(5):503\u201310.","journal-title":"Breast"},{"issue":"1","key":"442_CR17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-014-2914-x","volume":"145","author":"J Zhao","year":"2014","unstructured":"Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"442_CR18","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong J-H, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053\u201365.","journal-title":"N Engl J Med"},{"issue":"23","key":"442_CR19","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963\u20139.","journal-title":"J Clin Oncol"},{"key":"442_CR20","doi-asserted-by":"crossref","unstructured":"Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer. 2017;71:34\u201342.","DOI":"10.1016\/j.ejca.2016.10.030"},{"issue":"29","key":"442_CR21","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2011.36.4950","volume":"29","author":"JJ Griggs","year":"2011","unstructured":"Griggs JJ, Somerfield MR, Anderson H, et al. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol. 2011;29(29):3939\u201342.","journal-title":"J Clin Oncol"},{"issue":"4","key":"442_CR22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.clbc.2016.03.003","volume":"16","author":"RR Love","year":"2016","unstructured":"Love RR. Adjuvant surgical oophorectomy plus tamoxifen in premenopausal women with operable hormone receptor-positive breast cancer: a global treatment option. Clin Breast Cancer. 2016;16(4):233\u20137.","journal-title":"Clin Breast Cancer."},{"issue":"6","key":"442_CR23","doi-asserted-by":"crossref","first-page":"djv064","DOI":"10.1093\/jnci\/djv064","volume":"107","author":"RR Love","year":"2015","unstructured":"Love RR, Laudico AV, Van Dinh N, et al. Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer. J Natl Cancer Inst. 2015;107(6):djv064.","journal-title":"J Natl Cancer Inst"},{"key":"442_CR24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2016.03.011","volume":"60","author":"RR Love","year":"2016","unstructured":"Love RR, Hossain SM, Hussain MM, et al. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer. 2016;60:107\u201316.","journal-title":"Eur J Cancer"},{"issue":"3","key":"442_CR25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol. 2016;27(3):379\u201390.","journal-title":"Ann Oncol"},{"issue":"14","key":"442_CR26","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","volume":"34","author":"HJ Burstein","year":"2016","unstructured":"\u2022\u2022 Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689\u2013701. ASCO guidelines on ovarian suppression as adjuvant endocrine therapy for breast cancer patients.","journal-title":"J Clin Oncol"},{"issue":"14","key":"442_CR27","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","volume":"34","author":"M Bellet","year":"2016","unstructured":"Bellet M, Gray KP, Francis PA, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016;34(14):1584\u201393.","journal-title":"J Clin Oncol"},{"issue":"14","key":"442_CR28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.2015.65.3493","volume":"34","author":"A Papakonstantinou","year":"2016","unstructured":"Papakonstantinou A, Foukakis T, Rodriguez-Wallberg KA, Bergh J. Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? J Clin Oncol. 2016;34(14):1573\u20139.","journal-title":"J Clin Oncol"},{"issue":"19","key":"442_CR29","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","volume":"29","author":"G Pfeiler","year":"2011","unstructured":"Pfeiler G, K\u00f6nigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653\u20139.","journal-title":"J Clin Oncol"},{"issue":"14","key":"442_CR30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.2015.62.3728","volume":"34","author":"M Dowsett","year":"2016","unstructured":"Dowsett M, L\u00f8nning PE, Davidson NE. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. J Clin Oncol. 2016;34(14):1580\u20133.","journal-title":"J Clin Oncol"},{"issue":"9574","key":"442_CR31","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","volume":"369","author":"J Cuzick","year":"2007","unstructured":"LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711\u201323.","journal-title":"Lancet"},{"issue":"7","key":"442_CR32","first-page":"473","volume":"29","author":"S Jain","year":"2015","unstructured":"Jain S, Santa-Maria CA, Gradishar WJ. The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer. Oncol Williston Park N. 2015;29(7):473\u20138. 481","journal-title":"Oncol Williston Park N"},{"issue":"3","key":"442_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.breast.2014.03.011","volume":"23","author":"AH Partridge","year":"2014","unstructured":"\u2022 Partridge AH, Pagani O, Abulkhair O, et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209\u201320. International recommendations on the management of breast cancer in young women.","journal-title":"Breast"},{"issue":"35","key":"442_CR34","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","volume":"32","author":"AJ Tevaarwerk","year":"2014","unstructured":"Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948\u201358.","journal-title":"J Clin Oncol"},{"issue":"5","key":"442_CR35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436\u201346.","journal-title":"N Engl J Med"},{"issue":"14","key":"442_CR36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","volume":"34","author":"K Ribi","year":"2016","unstructured":"Ribi K, Luo W, Bernhard J, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol. 2016;34(14):1601\u201310.","journal-title":"J Clin Oncol"},{"issue":"9","key":"442_CR37","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/bjc.2016.71","volume":"114","author":"K-A Phillips","year":"2016","unstructured":"Phillips K-A, Regan MM, Ribi K, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956\u201364.","journal-title":"Br J Cancer"},{"issue":"10001","key":"442_CR38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"M Dowsett","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Dowsett M, Forbes JF, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"issue":"16","key":"442_CR39","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.ejca.2010.08.005","volume":"46","author":"KL Cheung","year":"2010","unstructured":"Cheung KL, Agrawal A, Folkerd E, et al. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer. 2010;46(16):2936\u201342.","journal-title":"Eur J Cancer"},{"issue":"25","key":"442_CR40","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","volume":"28","author":"RW Carlson","year":"2010","unstructured":"Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010;28(25):3917\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"442_CR41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/cncr.27818","volume":"119","author":"H Iwata","year":"2013","unstructured":"Iwata H, Masuda N, Sagara Y, et al. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. Cancer. 2013;119(4):704\u201313.","journal-title":"Cancer"},{"issue":"2","key":"442_CR42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2007.13.5319","volume":"26","author":"E Rossi","year":"2008","unstructured":"Rossi E, Morabito A, De Maio E, et al. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen\u00a0+\u00a0triptorelin in premenopausal patients with early breast cancer. J Clin Oncol. 2008;26(2):264\u201370.","journal-title":"J Clin Oncol"},{"issue":"7","key":"442_CR43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679\u201391.","journal-title":"N Engl J Med"},{"issue":"7","key":"442_CR44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631\u201341.","journal-title":"Lancet Oncol."},{"issue":"2","key":"442_CR45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313\u201320.","journal-title":"Ann Oncol"},{"issue":"2","key":"442_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107\u201318.","journal-title":"N Engl J Med"},{"issue":"7","key":"442_CR47","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","volume":"16","author":"J Bernhard","year":"2015","unstructured":"Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848\u201358.","journal-title":"Lancet Oncol"},{"issue":"2","key":"442_CR48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-015-3612-z","volume":"154","author":"MM Regan","year":"2015","unstructured":"Regan MM, Pagani O, Francis PA, et al. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015;154(2):275\u201386.","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"442_CR49","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","volume":"34","author":"MM Regan","year":"2016","unstructured":"Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221\u201331.","journal-title":"J Clin Oncol"},{"issue":"2","key":"442_CR50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jamaoncol.2015.5609","volume":"2","author":"TK Woodruff","year":"2016","unstructured":"Woodruff TK, Smith K, Gradishar W. Oncologists\u2019 role in patient fertility care: a call to action. JAMA Oncol. 2016;2(2):171\u20132.","journal-title":"JAMA Oncol"},{"issue":"9","key":"442_CR51","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/annonc\/mdt196","volume":"24","author":"NH Turner","year":"2013","unstructured":"Turner NH, Partridge A, Sanna G, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol. 2013;24(9):2224\u201335.","journal-title":"Ann Oncol"},{"key":"442_CR52","doi-asserted-by":"crossref","unstructured":"Lambertini M, Peccatori FA, Moore HC, Del Mastro L. Reply to the letter to the editor \"Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?\" by Rodriguez-Wallberg et al. Ann Oncol. 2016;27(3):548\u20139.","DOI":"10.1093\/annonc\/mdv599"},{"issue":"4","key":"442_CR53","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/AOG.0000000000001076","volume":"126","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Poggio F, Levaggi A, Del Mastro L. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126(4):901.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"442_CR54","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1634\/theoncologist.2015-0373","volume":"20","author":"L Del Mastro","year":"2015","unstructured":"Del Mastro L, Lambertini M. Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? Oncologist. 2015;20(11):1233\u20135.","journal-title":"Oncologist"},{"issue":"10","key":"442_CR55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HCF Moore","year":"2015","unstructured":"Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923\u201332.","journal-title":"N Engl J Med"},{"issue":"24","key":"442_CR56","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","volume":"314","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314(24):2632\u201340.","journal-title":"JAMA"},{"issue":"3","key":"442_CR57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jama.2011.991","volume":"306","author":"L Del Mastro","year":"2011","unstructured":"Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269\u201376.","journal-title":"JAMA"},{"issue":"12","key":"442_CR58","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/annonc\/mdv374","volume":"26","author":"M Lambertini","year":"2015","unstructured":"Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408\u201319.","journal-title":"Ann Oncol"},{"issue":"8","key":"442_CR59","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"\u2022 Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533\u201346. St. Gallen recommendations on the management of early stage breast cancer.","journal-title":"Ann Oncol"},{"key":"442_CR60","unstructured":"\u2022 National Comprehensive Cancer Network (NCC) Guidelines\u2014breast cancer. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf . NCCN guidelines on the management of breast cancer."},{"key":"442_CR61","doi-asserted-by":"crossref","unstructured":"\u2022 Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25\u201333. Italian Association of Medical Oncology recommendations on the use of temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients.","DOI":"10.1016\/j.ejca.2016.10.034"},{"key":"442_CR62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14694\/EDBK_159069","volume":"35","author":"HA Azim","year":"2016","unstructured":"Azim HA, Davidson NE, Ruddy KJ. Challenges in treating premenopausal women with endocrine-sensitive breast cancer. Am Soc Clin Oncol Educ Book. 2016;35:23\u201332.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"442_CR63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1586\/14737140.2016.1128327","volume":"16","author":"F Montemurro","year":"2016","unstructured":"Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. Expert Rev Anticancer Ther. 2016;16(2):211\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 2","key":"442_CR64","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.breast.2015.07.027","volume":"24","author":"A Mathew","year":"2015","unstructured":"Mathew A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast. 2015;24(Suppl 2):S120\u20135.","journal-title":"Breast"},{"issue":"20","key":"442_CR65","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2014.59.3673","volume":"33","author":"W He","year":"2015","unstructured":"He W, Fang F, Varnum C, et al. Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol. 2015;33(20):2262\u20139.","journal-title":"J Clin Oncol"},{"key":"442_CR66","doi-asserted-by":"crossref","unstructured":"Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107(10).","DOI":"10.1093\/jnci\/djv202"},{"issue":"3","key":"442_CR67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.breast.2015.01.005","volume":"24","author":"O Pagani","year":"2015","unstructured":"Pagani O, Ruggeri M, Manunta S, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015;24(3):201\u20137.","journal-title":"Breast"},{"key":"442_CR68","doi-asserted-by":"crossref","unstructured":"Pan H, Gray RG, Davies C, et al. Predictors of recurrence during years 5\u201314 in 46,138 women with ER+ breast cancer allocated 5\u00a0years only of endocrine therapy (ET). J Clin Oncol 2016;34(suppl):abstract 505.","DOI":"10.1200\/JCO.2016.34.15_suppl.505"},{"issue":"13","key":"442_CR69","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jnci\/djt134","volume":"105","author":"E Copson","year":"2013","unstructured":"Copson E, Eccles B, Maishman T, et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18\u201340\u00a0years at diagnosis: the POSH study. J Natl Cancer Inst. 2013;105(13):978\u201388.","journal-title":"J Natl Cancer Inst"},{"issue":"9869","key":"442_CR70","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805\u201316.","journal-title":"Lancet"},{"issue":"2","key":"442_CR71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/annonc\/mds330","volume":"24","author":"PE Goss","year":"2013","unstructured":"Goss PE, Ingle JN, Martino S, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol. 2013;24(2):355\u201361.","journal-title":"Ann Oncol"},{"issue":"6","key":"442_CR72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clbc.2014.04.007","volume":"14","author":"KJ Ruddy","year":"2014","unstructured":"Ruddy KJ, DeSantis SD, Barry W, et al. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014;14(6):413\u20136.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"442_CR73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10\u00a0years. N Engl J Med. 2016;375(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"442_CR74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JCO.2012.44.2285","volume":"31","author":"HA Azim Jr","year":"2013","unstructured":"Azim Jr HA, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"442_CR75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/bmt-2016-0009","volume":"5","author":"M Lambertini","year":"2016","unstructured":"Lambertini M, Del Mastro L. Fertility preservation in BRCA-mutated breast cancer patients. Breast Cancer Manag. 2016;5(2):61\u20138.","journal-title":"Breast Cancer Manag"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-017-0442-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-017-0442-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-017-0442-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T04:19:31Z","timestamp":1601612371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-017-0442-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["442"],"URL":"https:\/\/doi.org\/10.1007\/s11864-017-0442-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"article-number":"4"}}